Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

23.39 +0.02 (+0.09%)
Streaming Delayed Price Updated: 2:58 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript ↗
Jornay PM revenue surged 41% as Collegium integrated Azstarys and expanded its sales force. 
Via The Motley Fool
Topics Earnings
News headline image
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Man... 
Via StockStory
Topics Earnings
News headline image
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ... 
Via StockStory
Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance ↗
Via Chartmill
Collegium Pharmaceutical (NASDAQ:COLL) Surges on Q1 Earnings Beat as JORNAY PM Revenue Jumps 36% ↗
Via Chartmill
Topics Earnings
Collegium Pharmaceutical Inc (NASDAQ:COLL) Priced for a Value Rebound ↗
Via Chartmill
News headline image
Collegium Pharmaceutical Q2 Earnings Call Highlights ↗
Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower... 
Via MarketBeat
Topics Earnings
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ... 
Via StockStory
News headline image
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to look for. Collegium ... 
Via StockStory
News headline image
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Healthcare Stock with Competitive Advantages and 2 We Question
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial ... 
Via StockStory
News headline image
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
1 Mooning Stock to Own for Decades and 2 That Underwhelm
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne... 
Via StockStory
News headline image
2 Profitable Stocks to Keep an Eye On and 1 We Brush Off
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Approach with Caution
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
2 Reasons to Sell COLL and 1 Stock to Buy Instead
Shareholders of Collegium Pharmaceutical would probably like to forget the past six months even happened. The stock dropped 36.3% and now trades at $30.47. T... 
Via StockStory
Topics Supply Chain
News headline image
3 Growth Stocks We’re Skeptical Of
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
Collegium Pharmaceutical’s first quarter was marked by solid execution and positive market reaction, supported by robust growth in its ADHD and pain manageme... 
Via StockStory
Topics Earnings
News headline image
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
Via StockStory
Topics Economy
News headline image
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de... 
Via StockStory
News headline image
COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) announced better-than-expected revenue in Q1 CY2026, with sales up 8.9% year on year to $193.5 ... 
Via StockStory
News headline image
Collegium (COLL) Q1 2026 Earnings Transcript ↗
Collegium (COLL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 8.9% year o... 
Via StockStory
News headline image
Collegium Pharmaceutical (COLL) Q1 Earnings Report Preview: What To Look For
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors sho... 
Via StockStory
News headline image
1 Small-Cap Stock on Our Watchlist and 2 We Question
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
3 Reasons to Sell COLL and 1 Stock to Buy Instead
Over the last six months, Collegium Pharmaceutical’s shares have sunk to $32.78, producing a disappointing 5.8% loss - a stark contrast to the S&P 500’s 4% g... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
3 Cash-Producing Stocks Walking a Fine Line
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
1 Value Stock on Our Buy List and 2 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
Topics ETFs
News headline image
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Economy Stocks World Trade
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.